 |
|
| Faculty Staff | |
|
2019 |
Fourati S, Ribeiro SP, Blasco Tavares Pereira Lopes F, Talla A, Lefebvre F, Cameron M, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Rerks-Ngarm S, Kim JH, Thomas R, Gilbert PB, Tomaras GD, Koup RA, Michael NL, McElrath MJ, Gottardo R, Sekaly RP. Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. Nat Commun. 2019 Feb; 10: 863. | ||
2018 |
Garland SM, Joura EA, Ault KA, Bosch FX, Brown DR, Castellsague X, Ferenczy A, Ferris DG, Giuliano AR, Hernandez-Avila M, Huh WK, Iversen OE, Kjaer SK, Kurman RJ, Luna J, Monsonego J, Munoz N, Paavonen J, Pitisuttihum P, Ronnett BM, Steben M, Stoler MH, Wheeler CM, Wiley DJ, Perez G, Saah AJ, Luxembourg A, Li S, DiNubile MJ, Wagner M, Velicer C. Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age. Obstet Gynecol. 2018 Aug; 132(2): 261-70. | ||
| Pitisuttithum P, Chokephaibulkit K, Sirivichayakul C, Sricharoenchai S, Dhitavat J, Pitisuthitham A, Phongsamart W, Boonnak K, Lapphra K, Sabmee Y, Wittawatmongkol O, Chauhan M, Wijagkanalan W, Hommalai G, Fortuna L, Chinwangso P, Poredi IK, van den Biggelaar AHJ, Pham HT, Viviani Sal. Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority tri. Lancet Infect Dis. 2018 Nov; 18(11): 1260-8. | |||
| Pasin C, Halloran ME, Gilbert PB, Langevin E, Ochiai RL, Pitisuttithum P, Capeding MR, Carrasquilla G, Frago C, Cortes M, Chambonneau L, Moodie Z. Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease. PLoS ONE. 2018 Dec; 13(12): e0207878. | |||
| Wills S, Hwang KK, Liu P, Dennison SM, Tay MZ, Shen X, Pollara J, Lucas JT, Parks R, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Thomas R, Kim JH, Michael NL, Robb ML, McRaven M, Montefiori DC, Hope TJ, Liao HX, Moody MA, Ferrari G, Haynes BF, Alam SM, Bonsignori M, Tomaras GD. HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. Journal of Virology. 2018 Apr; 92(7): e01552-17. | |||
| Ndaya-Oloo P, Pitisuttithum P, Tornieporth NG, Desgrandchamps D, Munoz FM, Kochhar S, Buttery J, Bauwens J, Bonhoeffer J. Vaccine Update: Recent Progress With Novel Vaccines, and New Approaches to Safety Monitoring and Vaccine Shortage. J Clin Pharmacol. 2018 Oct;58 | |||
| Pissani F, Schulte B, Eller MA, Schultz BT, Ratto-Kim S, Marovich M, Thongcharoen P, Sriplienchan S, Rerks-Ngarm S, Pitisuttithum P, Esser S, Alter G, Robb ML, Kim JH, Michael NL, Streeck H10. Modulation of Vaccine-induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans. J Virol. Sep 12. pii: JVI.01143-18. | |||
| Barouch DH, Tomaka FL, Wegmann F, Stieh DJ, Alter G, Robb ML, Michael NL, Peter L, Nkolola JP, Borducchi EN, Chandrashekar A, Jetton D, Stephenson KE, Li W, Korber B, Tomaras GD, Montefiori DC, Gray G, Frahm N, McElrath MJ, Baden L, Johnson J, Hutter J, Swann E, Karita E, Kibuuka H, Mpendo J, Garrett N, Mngadi K, Chinyenze K, Priddy F, Lazarus E, Laher F, Nitayapan S, Pitisuttithum P, Bart S, Campbell T, Feldman R, Lucksinger G, Borremans C, Callewaert K, Roten R, Sadoff J, Scheppler L, Weijtens M, Feddes-de Boer K, van Manen D, Vreugdenhil J, Zahn R, Lavreys L, Nijs S, Tolboom J, Hendriks J, Euler Z, Pau MG, Schuitemaker H. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018 Jul 21;392(10143):232-243. | |||
| Scinto HB, Gupta S, Thorat S, Mukhtar MM, Griffiths A, Delgado J, Plake E, Vyas HK, Strickland A, Byrareddy SN, Montefiori DC, LaBranche C, Pal R, Treece J, Orndorff S6, Ferrari MG, Weiss D, Chenine AL, McLinden R, Michael N, Kim JH7, Robb ML, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Ruprecht RM. Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism. J Virol. 2018 Jun 29;92(14). | |||
| Yates NL, deCamp AC, Korber BT, Liao HX, Irene C, Pinter A, Peacock J, Harris LJ, Sawant S, Hraber P, Shen X, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Berman PW, Robb ML, Pantaleo G, Zolla-Pazner S, Haynes BF, Alam SM, Montefiori DC, Tomaras GD*.HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. Journal of Virology. 2018 Apr92(8): e01843-17 | |||
| Akapirat S, Karnasuta C, Vasan S, Rerks-Ngarm S, Pitisuttithum P, Madnote S, Savadsuk H, Rittiroongrad S, Puangkaew J, Phogat S, Tartaglia J, Sinangil F, de Souza MS, Excler JL, Kim JH, Robb ML, Michael NL, Ngauy V, O'Connell RJ, Karasavvas N*. Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. PLoS One. 2018 Apr 13(4): e0196397 | |||
| Plennevaux E*, Moureau A, Arredondo-Garcia JL, Villar L, Pitisuttithum P, Tran NH, Bonaparte M, Chansinghakul D, Coronel DL, L'Azou M, Leon Ochiai R, Toh ML, Noriega F, Bouckenooghe A. Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials. Clinical Infectious Diseases. 2018 Apr 66(8): 1164–72 | |||
| Auclair S, Liu F, Niu Q, Hou W, Churchyard G, Morgan C, Frahm N, Nitayaphan S, Pitisuthithum P, Rerks-Ngarm S, Kimata JT, Soong L, Franchini G, Robb M, Kim J, Michael N, Hu H. Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection. PLoS Pathogens. 2018 Feb 14(2): e1006888 | |||
| Garland SM*, Pitisuttithum P, Ngan HYS, Cho CH, Lee CY, Chen CA, Yang YC, Chu TY, Twu NF, Samakoses R, Takeuchi Y, Cheung TH, Kim SC, Huang LM, Kim BG, Kim YT, Kim KH, Song YS, Lalwani S, Kang JH, Sakamoto M, Ryu HS, Bhatla N, Yoshikawa H, Ellison MC, Han SR, Moeller E, Murata S, Ritter M, Sawata M, Shields C, Walia A, Perez G, Luxembourg A. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries. Journal of Infectious Diseases. 2018 Jun 218(1): 95-108 | |||
| Sricharoenchai S, Sirivichayakul C, Chokephaibulkit K, Pitisuttithum P, Dhitavat J, Pitisuthitham A, Phongsamart W, Boonnak K, Lapphra K, Sabmee Y, Wittawatmongkol O, Chinwangso P, Poredi IK, Petre J, Thai PH, Viviani S*. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial. Lancet Infectious Diseases. 2018 Jan 18(1): 58-67 | |||
2017 |
Boonnak K, Dhitavat J, Thantamnu N, Kosoltanapiwat N, Auayporn M, Jiang L, Puthavathana P, Pitisuttithum P. Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group. Vaccine. 2017 Dec 35(52): 7339-46 | ||
| El Fezzazi H, Branchu M, Carrasquilla G, Pitisuttithum P, Perroud AP, Frago C, Coudeville L*.Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine. American Journal of Tropical Medicine and Hygiene. 2017 Dec 97(6): 1898-903. | |||
| Wang K, Tomaras GD, Jegaskanda S, Moody MA, Liao HX, Goodman KN, Berman PW, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Haynes BF, Cohen JI*. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. Journal of Virology. 2017 Oct 91(19): e00411-17 | |||
| Perez LG, Martinez DR, deCamp AC, Pinter A, Berman PW, Francis D, Sinangil F, Lee C, Greene K, Gao H, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, O'Connell RJ, Robb ML, Michael NL, Kim JH, Gilbert P, Montefiori DC*.V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. PLoS One. 2017 Jul 12(7): e0180720. | |||
| Gilbert PB, Excler JL, Tomaras GD, Carpp LN, Haynes BF, Liao HX, Montefiori DC, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Kijak GH, Tovanabutra S, Francis DP, Lee C, Sinangil F, Berman PW, Premsri N, Kunasol P, O'Connell RJ, Michael NL, Robb ML, Morrow R, Corey L, Kim JH.Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. PLoS One. 2017 May 11;12(5):e0176428. Harrison SC, Haynes BF, Karnasuta C, et al. Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens. PLoS pathogens 2017; 33(5): 410-23. | |||
| Wills S, Hwang KK, Liu P, Dennison SM, Tay MZ, Shen X, Pollara J, Lucas JT, Parks R, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Thomas R, Kim JH, Michael NL, Robb ML, McRaven M, Montefiori DC, Hope TJ, Liao HX, Moody MA, Ferrari G, Haynes BF, Alam SM, Bonsignori M, Tomaras GD. HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. Journal of Virology. 2018 Apr 92(7): e01552-17 | |||
| Wang Y, Whittall T, Neil S, Britton G, Mistry M, Rerks-Ngarm S, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Yu X, Sato A, O'Connell RJ, Michael NL, Robb ML, Kim JH, Lehner T. A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection. Sci Rep. 2017 Apr 21;7(1):1057. | |||
| Pitisuttithum P*, Boonnak K, Chamnanchanunt S, Puthavathana P, Luvira V, Lerdsamran H, Kaewkungwal J, Lawpoolsri S, Thanachartwet V, Silachamroon U, Masamae W, Schuetz A, Wirachwong P, Thirapakpoomanunt S, Rudenko L, Sparrow E, Friede M, Kieny M-P. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases. 2017 Aug 17(8): 833-42 | |||
| Rerks-Ngarm S, Pitisuttithum P, Excler JL, Nitayaphan S, Kaewkungwal J, Premsri N, Kunasol P, Karasavvas N, Schuetz A, Ngauy V, Sinangil F, Dawson P, deCamp AC, Phogat S, Garunathan S, Tartaglia J, DiazGranados C, Ratto-Kim S, Pegu P, Eller M, Karnasuta C, Montefiori DC, Sawant S, Vandergrift N, Wills S, Tomaras GD, Robb ML, Michael NL, Kim JH, Vasan S, O'Connell RJ; RV305 Study Team. Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. J Infect Dis. 2017 Apr 15;215(8):1255-1263. | |||
| Easterhoff D, Moody MA, Fera D, Cheng H, Ackerman M, Wiehe K, Saunders KO, Pollara J, Vandergrift N, Parks R, Kim J, Michael NL, O'Connell RJ, Excler JL, Robb ML, Vasan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Sinangil F, Tartaglia J, Phogat S, Kepler TB, Alam SM, Liao HX, Ferrari G, Seaman MS, Montefiori DC, Tomaras GD, Harrison SC, Haynes BF. Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog. 2017 Feb 24;13(2):e1006182. | |||
| Karnasuta C, Akapirat S, Madnote S, Savadsuk H, Puangkaew J, Rittiroongrad S, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Tartaglia J, Sinangil F, Francis DP, Robb ML, de Souza MS, Michael NL, Excler JL, Kim JH, O'Connell RJ, Karasavvas N. Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens. AIDS Res Hum Retroviruses. 2017 May;33(5):410-423. |
|||
2016 |
Luo K, Liao HX, Zhang R, Easterhoff D, Wiehe K, Gurley TC, Armand LC, Allen AA, Von Holle TA, Marshall DJ, Whitesides JF, Pritchett J, Foulger A, Hernandez G, Parks R, Lloyd KE, Stolarchuk C, Sawant S, Peel J, Yates NL, Dunford E, Arora S, Wang A, Bowman CM, Sutherland LL, Scearce RM, Xia SM, Bonsignori M, Pollara J, Edwards RW, Santra S, Letvin NL, Tartaglia J, Francis D, Sinangil F, Lee C, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Michael NL, Kim JH, Alam SM, Vandergrift NA, Ferrari G, Montefiori DC, Tomaras GD, Haynes BF, Moody MA. Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. JCI Insight. 2016 Dec 8;1(20):e88522. | ||
| Astronomo RD, Santra S, Ballweber-Fleming L, Westerberg KG, Mach L, Hensley-McBain T, Sutherland L, Mildenberg B, Morton G, Yates NL, Mize GJ, Pollara J, Hladik F, Ochsenbauer C, Denny TN, Warrier R, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Ferrari G, Shaw GM, Xia SM, Liao HX, Montefiori DC, Tomaras GD, Haynes BF, Juliana McElrath M. Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine. 2016 Dec;14:97-111 | |||
| Pitisuttithum P, Bouckenooghe A. The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection. Expert Rev Vaccines. 2016 Jul;15(7):795-8. | |||
| Pitisuttithum P, Islam D, Chamnanchanunt S, Ruamsap N, Khantapura P, Kaewkungwal J, Kittitrakul C, Luvira V, Dhitavat J, Venkatesan MM, Mason CJ, Bodhidatta L. Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults. Clin Vaccine Immunol. 2016 Jul 5;23(7):564-75. | |||
2015 |
baldwin KM, Ehrenberg PK, Geretz A, Prentice HA,Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, O’Connell RJ, Kim JH, Thomas R. HLA class ll diversity in HIV-1 uninfected individuals form the placebo arm of the RV144 Thai vaccine efficacy trial.Tissue Antigens 2015 Feb 85(2):117-26 | ||
| Choi I, Chung AW, Suscovich TJ, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, O'Connell RJ, Francis D, Robb ML, Michael NL, Kim JH, Alter G, Ackerman ME, Bailey-Kellogg C.Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees. PLoS Comput Biol. 2015 Apr 11(4):e1004185. | |||
| Edlefsen PT, Rolland M, Hertz T, Tovanabutra S, Gartland AJ, deCamp AC, Magaret CA, Ahmed H, Gottardo R, Juraska M, McCoy C, Larsen BB, Sanders-Buell E, Carrico C, Menis S, Bose M; RV144 Sequencing Team, Arroyo MA, O'Connell RJ, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Robb ML, Kirys T, Georgiev IS, Kwong PD, Scheffler K, Pond SL, Carlson JM, Michael NL, Schief WR, Mullins JI, Kim JH, Gilbert PB.Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. PLoS Comput Biol. 2015 Feb 11(2):e1003973. | |||
| Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortés M, Pitisuttithum P ,Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M; CYD-TDV Dengue Vaccine Working Group.Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med. 2015 Sep 24;373(13):1195-206. | |||
| Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A; Broad Spectrum HPV Vaccine Study.A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015 Feb 372(8):711-23 | |||
| Janes H, Herbeck JT, Tovanabutra S, Thomas R, Frahm N, Duerr A, Hural J, Corey L, Self SG, Buchbinder SP, McElrath MJ, O'Connell RJ, Paris RM, Rerks-Ngarm S, Nitayaphan S, Pitisuttihum P, Kaewkungwal J, Robb ML, Michael NL, Mullins JI, Kim JH, Gilbert PB, Rolland M.HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. Nat Med. 2015 Oct (10):1139-41 | |||
| Karasavvas N, Karnasuta C, de Souza MS, Inthawong D, Savadsuk H, Madnote S, Chantakulkij S, Rittiroongrad S, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Siriyanon V, Andrews C, Barnett SW, Tartaglia J, Sinangil F, Francis DP, Robb M, Michael NL, Ngauy V, Paris RM, Excler DJ, Kim JH, O'Connell RJ. IgG Antibody Responses to Recombinant gp120 proteins, gp70V1/V2 Scaffolds and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials using Different Vaccine Regimens. AIDS Res Hum Retroviruses. 2015 Nov;31(11):1178-86. | |||
| Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, Scriba TJ, Mahomed H, Hanekom W, Bart PA, Pantaleo G, Tomaras GD, Rerks-Ngarm S, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Michael NL, Kim JH, Robb ML, O'Connell RJ, Karasavvas N, Gilbert P, C De Rosa S, McElrath MJ, Gottardo R.COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol. 2015 Jun;33(6):610-6. | |||
| Nicely NI, Wiehe K, Kepler TB, Jaeger FH, Dennison SM, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Robb ML, O'Connell RJ, Michael NL, Kim JH, Liao HX, Munir Alam S, Hwang KK, Bonsignori M, Haynes BF.Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. EBioMedicine. 2015 Jul 2(7):713-22 | |||
| Pitisuttithum P, Rerks-Ngarm S, Stablein D, Dawson P, Nitayaphan S, Kaewkungwal J, Michael NL, Kim JH, Robb ML, O'Connell RJ, Yoon IK, Fernandez S, Excler JL.Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand. PLoS One. 2015 May 10(5):e0127998. | |||
| Prentice HA, Tomaras GD, Geraghty DE, Apps R, Fong Y, Ehrenberg PK, Rolland M, Kijak GH, Krebs SJ, Nelson W, DeCamp A, Shen X, Yates NL, Zolla-Pazner S, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Ferrari G, McElrath MJ, Montefiori DC, Bailer RT, Koup RA, O'Connell RJ, Robb ML, Michael NL, Gilbert PB, Kim JH, Thomas R.HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. Sci Transl Med. 2015 Jul 7(296):296ra112. | |||
| Pitisuttithum P, Velicer C, Luxembourg A. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.Expert Review of Vaccines 2015 Nov 14(11):1405-19 | |||
| Peachman KK, Karasavvas N, Chenine AL, McLinden R, Rerks-Ngarm S, Jaranit K, Nitayaphan S, Pitisuttithum P, Tovanabutra S, Zolla-Pazner S, Michael NL, Kim JH, Alving CR, Rao M.Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor. PLoS One. 2015 Dec 1;10(12):e0143895. | |||
| Santra S, Tomaras GD, Warrier R, Nicely NI, Liao HX, Pollara J, Liu P, Alam SM, Zhang R, Cocklin SL, Shen X, Duffy R, Xia SM, Schutte RJ, Pemble Iv CW, Dennison SM, Li H, Chao A, Vidnovic K, Evans A, Klein K, Kumar A, Robinson J, Landucci G, Forthal DN, Montefiori DC, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, Michael NL, Kim JH, Soderberg KA, Giorgi EE, Blair L, Korber BT, Moog C, Shattock RJ, Letvin NL, Schmitz JE, Moody MA, Gao F, Ferrari G, Shaw GM, Haynes BF. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathog. 2015 Aug 3;11(8):e1005042. | |||
| Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, Huang LM, Kim DS, Pitisuttithum P, Chen J, Christiano S, Maansson R, Moeller E, Sun X, Vuocolo S, Luxembourg A.Immunogenicity and Safety of a 9-Valent HPV Vaccine. Pediatrics. 2015 Jul;136(1):e28-39 | |||
| Vasan S, Rerks-Ngarm S, Gilbert P, Haynes B, Nitayapan S, Pitisuttihum P, Kaewkungwal J, Excler JL, Robb M, Michael N, Kim J, O'Connell R.Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection. in: Hum Vaccin Immunother. Apr 2015;11(4):1036-7 | |||
| Worasathit R, Wattana W, Okanurak K, Songthap A, Dhitavat J, Pitisuttithum P.Health education and factors influencing acceptance of and willingness to pay for influenza vaccination among older adults. BMC Geriatr. 2015 Oct 15(1):136. | |||
2014 |
Ana-Sosa-Batiz F*, Johnston AP, Liu H, Center RJ, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Kim JH, Michael NL, Kelleher AD, Stratov I, Kent SJ, Kramski M. HIV-specific antibody-dependent phagocytosis matures during HIV infection.Immunology and Cell Biology. 2014 Sep 92(8): 679-87 | ||
| Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D*, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014 Oct 384(9951): 1358-65 | |||
| Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, Dugast AS, Schoen MK, Rolland M, Suscovich TJ, Mahan AE, Liao L, Streeck H, Andrews C, Rerks-Ngarm S, Nitayaphan S, de Souza MS, Kaewkungwal J, Pitisuttithum P, Francis D, Michael NL, Kim JH, Bailey-Kellogg C, Ackerman ME, Alter G*. Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003. Vaccines Science Translational Medicine. 2014 Mar 6(228):228ra8 | |||
| Dennison SM, Anasti KM, Jaeger FH, Stewart SM, Pollara J, Liu P, Kunz EL, Zhang R, Vandergrift N, Permar S, Ferrari G, Tomaras GD, Bonsignori M, Michael NL, Kim JH, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Liao HX, Haynes BF, Alam SM*. Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. Journal of Virology 2014 Aug 88(16): 9406-17 | |||
| Dennison SM, Anasti KM, Jaeger FH, Stewart SM, Pollara J, Liu P, Kunz EL, Zhang R, Vandergrift N, Permar S, Ferrari G, Tomaras GD, Bonsignori M, Michael NL, Kim JH, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Liao HX, Haynes BF, Alam SM*. Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. Journal of Virology 2014 Aug 88(16): 9406-17 | |||
| Joura EA*, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Miller D, Monsonego J, Munoz N, Myers E, Paavonen J, Pitisuttithum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiology Biomarkers and Prevention 2014 Oct 23(10): 1997-2008 | |||
| Khowsroy K, Dhitavat J*, Sabmee Y, Laowarakul P, Wattanakitwichai J, Auetian J, Lothong K, Boondao R, Maythaarttaphong S, Yaemwong S, Excler JL, Rerks-Ngarm S, Pitisuttithum P. Expectation of Volunteers Towards the Vaccine Efficacy of the Prime-Boost HIV Vaccine Phase III Trial During Unblinding. AIDS Research and Human Retroviruses. 2014 Nov 30(11): 1041-5 | |||
| Li SS*, Gilbert PB*, Tomaras GD, Kijak G, Ferrari G, Thomas R, Pyo CW, Zolla-Pazner S, Montefiori D, Liao HX, Nabel G, Pinter A, Evans DT, Gottardo R, Dai JY, Janes H, Morris D, Fong Y, Edlefsen PT, Li F, Frahm N, Alpert MD, Prentice H, Rerks-Ngarm S, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Robb ML, O'Connell RJ, Haynes BF, Michael NL, Kim JH, McElrath MJ, Geraghty DE. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. Journal of Clinical Investigation. 2014 Sep 124(9): 3879-90 | |||
| Penezina O, Krueger NX, Rodriguez-Chavez IR, Busch MP, Hural J, Kim JH, O'Connell RJ, Hunter E, Aboud S, Higgins K, Kovalenko V, Clapham D, Crane D, Levin AE*, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Andrews C, Kilembe W, Karita E, Allen S, Munseri P, Joachim A, Bakari M, Mhalu F, Aris E, Nilsson C, Biberfeld G, Robb M, Marovich M, Sandstrom E. Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants. Clinical and Vaccine Immunology 2014 Mar 21(3): 391-8 | |||
| Pollara J, Bonsignori M, Moody MA, Liu PH, Alam SM, Hwang KK, Gurley TC, Kozink DM, Armand LC, Marshall DJ, Whitesides JF, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, O'Connell RJ, Kim JH, Michael NL, Montefiori DC, Tomaras GD, Liao HX, Haynes BF, Ferrari G*. HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. Journal of Virology. 2014 Jul 88(14): 7715-26 | |||
| Prentice HA, Ehrenberg PK, Baldwin KM, Geretz A, Andrews C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, O'Connell RJ, Robb ML, Kim JH, Michael NL, Thomas R*. HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial. Immunogenetics 2014 May 66(5):299-310 | |||
| Rid A*, Saxena A, Baqui AH, Bhan A, Bines J, Bouesseau MC, Caplan A, Colgrove J, Dhai A, Gomez-Diaz R, Green SK, Kang G, Lagos R, Loh P, London AJ, Mulholland K, Neels P, Pitisuttithum P, Sarr SC, Selgelid M, Sheehan M, Smith PG. Placebo use in vaccine trials: Recommendations of a WHO expert panel. Vaccine 2014 Aug 32(37): 4708-12 | |||
| Stieh DJ, King DF, Klein K, Liu P, Shen X, Hwang KK, Ferrari G, Montefiori DC, Haynes B, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Robb ML, Kim JH, Denny TN, Tomaras GD, Shattock RJ*. Aggregate complexes of HIV-1 induced by multimeric antibodies. Retrovirology. 2014 Oct 11(1):78 | |||
| Thanachartwet V, Desakorn V, Duangrithi D, Chunpongthong P, Phojanamongkolkij K, Jitruckthai P, Kasetjaroen Y, Pitisuttithum P*. Comparison of clinical and laboratory findings between those with pulmonary tuberculosis and those with nontuberculous mycobacterial lung disease. Southeast Asian Journal of Tropical Medicine and Public Health. 2014 Jan 45(1):85-94 | |||
| Wiehe K*, Easterhoff D, Luo K, Nicely NI, Bradley T, Jaeger FH, Dennison SM, Zhang R, Lloyd KE, Stolarchuk C, Parks R, Sutherland LL, Scearce RM, Morris L, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Sinangil F, Phogat S, Michael NL, Kim JH, Kelsoe G, Montefiori DC, Tomaras GD, Bonsignori M, Santra S, Kepler TB, Alam S, Moody MA, Liao HX, Haynes BF. Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. Immunity 2014 Dec 41(6): 909-18 | |||
| Yates NL, Liao HX, Fong YI, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, Berman PW, Alpert MD, Evans DT, O'Connell RJ, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Pinter A, Zolla-Pazner S, Gilbert PB, Nabel GJ, Michael NL, Kim JH, Montefiori DC, Haynes BF, Tomaras GD*. Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. Science Translational Medicine. 2014 Mar 6(228): 228ra39 | |||
| Yeekian C, Geratikornsupak N, Chumpongthong P, Tongsiri S, Dhitavat J, Phonrat B, Pitisuttithum P*. Medical and economic burden of chronic hepatitis B patients at Queen Savang Vadhana Memorial Hospital. Journal of the Medical Association of Thailand. 2014 Apr 97(4): 447-55 | |||
| Zolla-Pazner S*, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA, Irene C, Reichman C, Pinter A, Parks R, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Nitayaphan S, Andrews C, O'Connell RJ, Yang ZY, Nabel GJ, Kim JH, Michael NL, Montefiori DC, Liao HX, Haynes BF, Tomaras GD. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One 2014 Feb 9(2): e87572 | |||
| พรรณี ปิติสุทธิธรรม. วัคซีนป้องกันโรคเอดส์. ใน: โอฬาร พรหมาลิขิต, อัจฉรา ตั้งสถาพรพงษ์ และ อุษา ทิสยากร, บรรณาธิการ. วัคซีน. พิมพ์ครั้งที่ 2. กรุงเทพฯ: นพชัยการพิมพ์; 2558. หน้า 511-523. | |||
2013 |
Alam SM, Liao HX, Tomaras GD, Bonsignori M, Tsao CY, Hwang KK, Chen HY, Lloyd KE, Bowman C, Sutherland L, Jeffries TL, Kozink DM, Stewart S, Anasti K, Jaeger FH, Parks R, Yates NL, Overman RG, Sinangil F, Berman PW, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Karasavva N, Rerks-Ngarm S, Kim JH, Michael NL, Zolla-Pazner S, Santra S, Letvin NL, Harrison SC, Haynes BF. Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion. Journal of Virology. 2013 Feb 87(3):1554-68 | ||
| Aung KLL, Thanachartwet V*, Desakorn V, Chamnanchanunt S, Sahassananda D, Chierakul W, Pitisuttithum P. Factors associated with severe clinical manifestation of dengue among adults in Thailand. Southeast Asian Journal of Tropical Medicine and Public Health.2013 Jul 44(4):602-12 | |||
| Capeding MR, Chua MN, Hadinegoro SR, Hussain IIHM, Nallusamy R, Pitisuttithum P, Rusmil K, Thisyakorn U, Thomas SJ, Huu Tran N, Wirawan DN, Yoon I-K, Bouckenooghe A, Hutagalung Y, Laot T, Wartel TA. Dengue and Other Common Causes of Acute Febrile Illness in Asia: An Active Surveillance Study in Children. PLoS Neglected Tropical Diseases. 2013 Jul 7(7):e2331 | |||
| Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Rolland M, Dugast A, Suscovich TJ, Liao L, Mahan AE, Streeck H, Rerks-Ngarm S, Nitayaphan S, de Souza MS, Pitisuttithum P, Francis D, Michael NL, Kim JH, Bailey-Kellog C, Ackerman ME, Alter G. Distinct HIV-Specific Antibody Fc-Profiles in RV144 and VAX003 Vaccinees. AIDS Research and Human Retroviruses. 2013 Nov 29(11):A63-A4 | |||
| Duangrithi D,Thanachartwet V,Desakorn V,Jitruckthai P,Phojanamongkolkij K,Rienthong s,Chuchottaworn C,Pitisuttithum P. Impact of diabetes mellitus on clinical parameters and treatment outcomes of newly diagnosed pulmonary tuberculosis patients in Thailand. International Journal of Clinical Practice. 2013 Nov Pages1199-1209 | |||
| Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, Wenschuh H, Zerweck J, Greene K, Gao H, Berman PW, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Robb ML, Michael NL, Kim JH, Zolla-Pazner S, Haynes BF, Mascola JR, Self S, Gilbert P, Montefiori DC. Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial. Trial. PLoS One. 2013 Sep 26;8(9):e75665 | |||
| Kyaw NL, Thanachartwet V, Kiertiburanakul S, Desakorn V, Chamnanchanunt S, Chierakul W, Manosuthi W, Pitisuttithum P, Sungkanuparph S. Baseline CD4 cell counts and outcomes among adult treatment naïve HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand. Southeast Asian Journal of Tropical Medicine and Public Health. 2013 Mar 44(2):232-43 | |||
| Kaewkungwal J, Pitisuttithum P, Rerks-Ngarm S, Nitayaphan S, Khamboonruang C, Kunasol P, Suntharasamai P, Pungpak S, Vanijanonta S, Bussaratid V, Maek-A-Nantawat W, Dhitavat J, Thongcharoen P, Pawarana R, Sabmee Y, Benenson MW, Morgan P, O' Connell RJ, Kim J. Issues in Women's Participation in a Phase III Community HIV Vaccine Trial in Thailand. AIDS Res Hum Retroviruses. 2013 Nov 29(11):1524-34 | |||
| Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, Kozink DM, Hwang KK, Chen X, Tsao CY, Liu P, Lu X, Parks RJ, Montefiori DC, Ferrari G, Pollara J, Rao M, Peachman KK, Santra S, Letvin NL, Karasavvas N, Yang ZY, Dai K, Pancera M, Gorman J, Wiehe K, Nicely NI, Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Sinangil F, Kim JH, Michael NL, Kepler TB, Kwong PD, Mascola JR, Nabel GJ, Pinter A, Zolla-Pazner S, Haynes BF. Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. Immunity. 2013 Jan 38(1):176-86 | |||
| Liu P, Yates NL, Shen X, Bonsignori M, Moody MA, Liao HX, Fong Y, Alam SM, Overman RG, Denny T, Ferrari G, Ochsenbauer C, Kappes JC, Polonis V, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Montefiori DC, Gilbert P, Michael NL, Kim JH, Haynes BF, Tomaras GD. Infectious Virion Capture by HIV-1 gp120 Specific IgG from RV144 Vaccinees. J Virol. 2013 Jul;87(14):7828-36. | |||
| Phonrat B, Pitisuttithum P, Chamnanchanunt S, Puthavathana P, Ngaosuwankul N, Louisirirotchanakul S, Dhitavat J, Thirapakpoomanunt S, Chokevivat V, Wibulpolprasert S. Safety and immune responses following administration of H1N1 live attenuated influenza vaccine in Thais. Vaccine. 2013 Mar 31(11):1503-9 | |||
| Pitisuttithum P*, Excler J-L, Kim J. Beyond RV144 Efficacy Results: An Update. Procedia in Vaccinology. 2013 Jul 7:49-56 | |||
| Pitisuttithum P, Rerks-Ngarm S, O’Connell RJ, Kim JH, Excler JL. An HIV Vaccine for South-East Asia-Opportunities and Challenges. Vaccines 2013 1(3), 348-366 | |||
| Sagaki P1, Thanachartwet V, Desakorn V, Sahassananda D, Chamnanchanunt S, Chierakul W, Pitisuttithum P, Ruangkanchanasetr P. Clinical factors for severity of Plasmodium falciparum malaria in hospitalized adults in Thailand. PLoS One. 2013 Aug 12;8(8):e71503. | |||
| Thanachartwet V, Desakorn V,Duangrithi D,Chunpongthong P, Phojanamongkolkij K,Jitruckthai,Kasetjaroen Y,Pitisuttithum P. Comparison of clinical and laboratory findings between those with pulmonary tuberculosis and those with nontuberculous mycobacterial lung disease. southeast Asian J Tropmed Public Health. 2014 Jan Vol 45 Page 85 – 94 | |||
| Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, Bonsignori M, Moody MA, Fong Y, Chen X, Poling B, Nicholson CO, Zhang R, Lu X, Parks R, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Gilbert PB, Kim JH, Michael NL, Montefiori DC, Haynes BF. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Southeast Asian J Trop Med Public Health. 2013 Mar;44(2):232-43. | |||
2012 |
Alam SM, Liao HX, Tomaras GD, Bonsignori M, Tsao CY, Hwang KK, Chen H, Lloyd KE, Bowman C, Sutherland L, Jeffries TL Jr, Kozink DM, Stewart S, Anasti K, Jaeger FH, Parks R, Yates NL, Overman RG, Sinangil F, Berman PW, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Karasavva N, Rerks-Ngarm S, Kim JH, Michael NL, Zolla-Pazner S, Santra S, Letvin NL, Harrison SC, Haynes BF. Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen is Enhanced by a gp120 N-terminal Deletion. Journal of Virology 2012 Nov 86(21):115 21. | ||
| Bodhidatta L, Pitisuttithum P, Chamnanchanant S, Chang KT, Islam D, Bussaratid V, Venkatesan MM, Hale TL, Mason CJ. Establishment of a Shigella sonnei human challenge model in Thailand. Vaccine. 2012 Nov 19;30(49):7040-5 | |||
| Bonsignori M, Pollara J, Moody MA, Kepler TB, Chen X, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Montefiori DC, Liao H, Ferrari G, Haynes BF. Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Preferentially Use the VH1 Gene Family (Abstract). AIDS VACCINE 2012, Boston, USA, Sep 9-12, 2012 p.134. | |||
| De Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, et al. The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope. J Immunol. 2012 May 15;188(10):5166-5176. | |||
| Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012 Apr 5;366(14):1275-86. | |||
| Htun WL, Bowonwatanuwong C, Phonrat B, Pitisuttithum P. Long term outcomes of nevirapine containing antiretroviral therapy at a center in Thailand. Southeast Asian J Trop Med Public Health. 2012 Jul;43(4):860-870. | |||
| Jean-Louis Excler, Pitisuttithum P. Chapter 21 HIV Vaccine Development in Asia. In: Jai P. Narain, eds. Three Decades of HIV/AIDS in Asia. New Delhi: SAGE Publications India Pvt Ltd; 2012:364-385. | |||
| Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, Tomaras GD, Currier JR, Jiang M, Magaret C, Andrews C, Gottardo R, Gilbert P, Cardozo TJ, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Paris R, Greene K, Gao H, Gurunathan S, Tartaglia J, Sinangil F, Korber BT, Montefiori DC, Mascola JR, Robb ML, Haynes BF, Ngauy V, Michael NL, Kim JH, de Souza MS; MOPH TAVEG Collaboration. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses. 2012 Nov;28(11):1444-57 | |||
| Luvira V, Chamnanchanunt S, Bussaratid V, Leaungwutiwong P, Pitisuttithum P. Seroprevalence of Latent Cytomegalovirus Infection among Elderly Thais. Southeast Asian J Trop Med Public Health. 2012 Nov; 43(6):1419-25. | |||
| Liao L, Bonsignori M, Hwang K, Moody AM, Park R, Crawford S, Chen H, Jeffries TL, Cooper M, Lu X, De R, Karasavvas N, Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J, Tovanabutra S, Pitisuttithum P, Tartaglia J, Sinangil F, Kim J, Michael NL, Tomaras GD, Yang Z, Dai K, Pancera M, Nabel GJ, Mascola JR, Kwong PD, Pinter A, Zolla-Pazner S, Alam MS, Haynes BF. Design of an HIV Env Antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2 (Abstract). AIDS VACCINE 2012, Boston, USA, Sep 9-12, 2012 p.69. | |||
| Matys K, Mallary S, Bautista O, Vuocolo S, Manalastas R, Pitisuttithum P, Saah A. Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine. Clin Vaccine Immunol. 2012 Jun;19(6):881-5 | |||
| Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, Greene K, Gao H, Labranche CC, Andrews C, Polonis VR, Rerks-Ngarm S, Pitisuttithum P, et al. Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. J Infect Dis. 2012 Jun 14. | |||
| Paris R, Bejrachandra S, Thongcharoen P, Nitayaphan S, Pitisuttithum P, Sambor A, Gurunathan S, Francis D, Ratto-Kim S, Karnasuta C, de Souza MS, Polonis VR, Brown AE, Kim JH, Stephens HA; for the Thai AIDS Vaccine Evaluation Group (Taveg). HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E. Vaccine. 2012 Jan 20;30(5):832-836. | |||
| Pollara J, Bonsignori M, Moody M, Alam M, Liao H, Hwang K, Pickeral J, Kappes J, Ochsenbauer c, Soderberg K, Gurley TC, Kozink DM, Marshall DJ, Whitesdies JF, Montefiori D, Robinson JE, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim J, Michael N, Tomaras G, Haynes BF, Ferrari G. Vaccine-induced ADCC-Mediating antibodies target unique and overlapping envelope epitopes (Abstract). AIDS VACCINE 2012, Boston, USA, Sep 9-12, 2012 p.73. | |||
| Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis. 2012 May 29; 12: 531-37. | |||
| Songthap A, Pitisuttithum P, Kaewkungwal J, Fungladda W, Bussaratid B. Knowledge, attitude, and acceptability of a human papiloma virus vaccine among students, parents and teachers in Thailand. Southeast Asian J Trop Med Public Health. 2012 Mar; 43(2):340-353. | |||
| Than NN, Sungkanuparph S, Maek-A-Nantawat W, Kaewkungwal J, Pitisuttithum P. Comparison of clinical outcomes between HIV-infected patients with and without HCV co-infection in a resource-limited setting. Southeast Asian Journal of Tropical Medicine and Public Health. 2012 May 43(3):646-51 | |||
2011 |
Alpert MD, Harvey JD, Neidermyer WJ, Huang Y, Morris D, Harris L, Gao H, Montefiori DC, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim J, Evans DT. ADCC titers to HIV-infected cells are detectable in the majority of vaccine recipients in the RV144 trial (Oral Presentation). AIDS VACCINE 2011, Bangkok, Thailand, Sep 12-15, 2011 p.76. | ||
| Aunhachoke K, Bussaratid V, Chirachanakul P, Chua-Intra B, Dhitavat J, Jaisathaporn K, Kaewkungwal J, Kampirapap K, Khuhaprema T, Pairayayutakul K, Pitisuttithum P, Sindhvananda J, Thaipisuttikul Y; for the Thai Herpes Zoster Study Group. Measuring herpes zoster, zoster-associated pain, post-herpetic neuralgia-associated loss of quality of life, and healthcare utilization and costs in Thailand. Int J Dermatol. 2011 Apr;50(4):428-435. | |||
| Billings EA, Karasavvas N, De Souza MS, Currier J, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Gilbert PB, Tomaras GD, Zolla-Pazner SB, Haynes BF, Nichael NL, Rerks-Ngarm S, Kim J, Rao M. Surface Plasmon resonance analysis of anti-gp120 V2-specific IgG antibodies generated in the RV144 Thai trial (Oral Presentation). AIDS VACCINE 2011, Bangkok, Thailand, Sep 12-15, 2011 p.77. | |||
| Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, Bryan J, Vuocolo S, Haupt RM, Saah A. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011 May 31. | |||
| Chunpongthong P, Win Ko Ko Z, Yeekian C, Luvira V, Pitisuttithum P. Outcomes of antituberculosis treatments at 18 months follow-up in TB-HIV co-infected patients on ART: a retrospective review of 166 cases. J Med Assoc Thai 2011; 94 (6): 664-670. | |||
| Desakorn V, Karmacharya BM, Thanachartwet V, Kyaw NL, Tansuphasawadikul S, Sahassananda D, Dhitavat J, Maek-a-nantawat W, Pitisuttithum P. Effectiveness of fixed-dose combination stavudine, lamivudine and nevirapine (GPO-VIR) for treatment of naïve HIV patients in Thailand: a 3-year follow-up. Southeast Asian J Trop Med Public Health. 2011 Nov;42(6):1414-1422. | |||
| Karasavvas N, Billings E, Rao M, Currier J, Michael NL, Rerks-Ngarm S, Pitisuttithum P, Kaewkungwal J, Ngauy V, Nitayaphan S, Madnote S, Arworn D, Kim J, De Souza M. The Thai Phase Iii clinical trial (RV144) induces the generation of antibodies that target a conserved region within the V2 loop of gp120 (Oral Presentation). AIDS VACCINE 2011, Bangkok, Thailand, Sep 12-15, 2011 p.71. | |||
| Larsen RA, Bauer M, Pitisuttithum P, Sanchez A, Tansuphaswadikul S, Wuthiekanun V, Peacock SJ, Simpson AJ, Fothergill AW, Rinaldi MG, Bustamante B, Thomas AM, Altomstone R, Day NP, White NJ. CORRELATION OF SUSCEPTIBILITY TESTING OF C. NEOFORMANS TO AMPHOTERICIN B WITH CLINICAL OUTCOME. Antimicrob Agents Chemother. 2011 Sep 26. | |||
| Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maekanantawat W, Pungpak S, Suntharasamai P, Vanijanonta S, Nitayapan S, Kaewkungwal J, Benenson M, Morgan P, O'Connell RJ, Berenberg J, Gurunathan S, Francis DP, Paris R, Chiu J, Stablein D, Michael NL, Excler JL, Robb ML, Kim JH. Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand. PLoS One. 2011;6(12): e27837. | |||
| Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maekanantawat W, Pungpak S, Suntharasamai P, Vanijanonta S, Nitayaphan S, Kaewkungwal J, Chunsuttiwat, S, Premsri N, Benenson M, Morgan P, Berenberg J, Gurunathan S, Francis DP, Chiu J, Excler J, Robb ML, Stablein D, Michael NL, Kim J. Safety and Reactogenicity of ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Prime-Boost vaccination regimen in a community-based efficacy trial (Abstract). AIDS VACCINE 2011, Bangkok, Thailand, Sep 12-15, 2011 p.156. | |||
| Pitisuttithum P, Rerks-Ngarm S, Chiu J, Kim J, Benenson M, Kent SJ, Tamashiro H, Manrique A, Bernstein A, Goyal R, Ditangco RA, Cooper DA, Osmanov S, Mathieson B, Sandstrom E, Esparza J, Hoff R, Shao Y for the AIDS Vaccine for Asia Network. Accelerating the development of an AIDS Vaccine: The AIDS Vaccine for Asia Network (AVAN). Southeast Asian J Trop Med Public Health. 2011 Sep;42(5):1130-1146. | |||
| Pitisuttithum P. Thailand’s contribution to HIV vaccine research and development (Abstract). AIDS VACCINE 2011, Bangkok, Thailand, Sep 12-15, 2011 p.21. | |||
| The Ministry of Public Health - Thai AIDS Vaccine Evaluation Group (MOPH-TAVEG). Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148). Vaccine 29 (2011) 4285–4292. | |||
2010 |
Aramaki M, Silachamroon U, Desakorn V, Maek-A-nantawat W, Waiwaruwut J, Jutiwarakun K, Kim JH, Pitisuttithum P. Immune reconstitution inflammatory syndrome in adult human immunodeficiency virus-infected patients in Thailand. Southeast Asian J Trop Med Public Health. 2010 Jan;41(1):138-45. | ||
| Baldwin K, Cervenka T, De Souza MS, Paris R, Koehler R, Thongcharoen P, Pitisuttithum P, Nitayaphan S, Suriyanon V, Robb M, Michael N, Kim J, Kijak G, and the TAVEG. Genetics of Fc Gamma Receptors IIa and IIIa in vaccine trial reagents to support the study of immune correlates in RV144 (Abstract). AIDS VACCINE 2010, Atlanta, USA, Sep 28-Oct 1, 2010 p.158 | |||
| Cervenka T, Baldwin K, De Souza MS, Paris R, Koehler R, Thongcharoen P, Pitisuttithum P, Nitayaphan S, Suriyanon V, Robb M, Michael N, Kim J, Kijak G, and the TAVEG. Feasibility of high-throughout and low-cost high-resolution class I HLA typing of HIV vaccine trial cohorts in Southeast Asia (Abstract). AIDS VACCINE 2010, Atlanta, USA, Sep 28-Oct 1, 2010 p.157 | |||
| Jayathunge MP, Bowanwatanuwong C, Maek-A-nantawat W, Pitisuttithum P. Psychosocial burden of abnormal pap smears among HIV-infected women at Chon Buri hospital, Thailand. Southeast Asian J Trop Med Public Health. 2010 Jan;41(1):224-34. | |||
| Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Stablein D, Chiu J, Benenson M, Kim J, Robb M, Michael N, Rerks-Ngarm S. Exploratory Age-stratified analysis of risk-taking behaviors and trial participation outcomes in the Thai phase III HIV vaccine trial (Oral Presentation). AIDS VACCINE 2010, Atlanta, USA, Sep 28-Oct 1, 2010 p.66 | |||
| Kent SJ, Cooper DA, Chhi Vun M, Shao Y, Zhang L, Ganguly N, Bela B, Tamashiro H, Ditangco R, Rerks-Ngarm S, Pitisuttithum P, Van Kinh N, Bernstein A, Osmanov S; AIDS Vaccine for Asia Network investigators and supporters. AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines. PLoS Med. 2010 Sep 21;7(9):e1000331. | |||
| Martin M, Vanichseni S, Suntharasamai P, Mock PA, van Griensven F, Pitisuttithum P, Tappero JW, Chiamwongpaet S, Sangkum U, Kitayaporn D, Gurwith M, Choopanya K; for the Bangkok Vaccine Evaluation Group. Drug use and the risk of HIV infection amongst injection drug users participating in an HIV vaccine trial in Bangkok, 1999-2003. Int J Drug Policy. 2010 Jul;21(4):296-301 | |||
| Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, Wolfe ND, Aste-Amezaga M, Casimiro DR, Coplan P, Straus WL, Shiver JW. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2010 Jan 22;28(4):950-7. | |||
| Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson MN, Mehrotra DV, Self S, Turner K, Sanchez J, Pitisuttithum P, Duerr A, Dubey S, Kierstead L, Casimiro D, Hammer SM; for the Merck V520-018/HIV Vaccine Trials Network 050 Study Team. Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. AIDS Res Hum Retroviruses. 2010 Nov 23. | |||
| Pitisuttithum P, Choopanya K, Rerk-Ngnam S. HIV-vaccine research and development in Thailand: evolution and challenges. Vaccine. 2010 May 26;28 Suppl 2:B45-9. | |||
| Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maek-a-nantawat W, Pungpak S, Suntharasamai P, Vanijanonta S, Nitayaphan S, Kaewkungwal J, Benenson MW, Chiu J, Robb ML, Gurunathan S, Francis D, Stablein DM, Kim J. Safety profiles of ALVAC HIV and AIDSVAX vaccines in the Phase III community based trial in Thailand (Abstract). AIDS VACCINE 2010, Atlanta, USA, Sep 28-Oct 1, 2010 p.193 | |||
| Rerks-Ngarm S, Pitisuttithum P, Ganguly N, Zhang L, Tamashiro H, Cooper DA, Vun MC, Bela B, Ditangco R, Van KN, Bernstein A, Osmanov S, Mathieson B, Kent SJ, Shao Y. Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding. Current Opinion in HIV & AIDS. 5(5):435-452, September 2010. | |||
| Rerks-Ngarm S, Premsri N, Namwat C, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Kingko P, Jirasethasiri M, Paris R, Chiu J, Kim J, Khamboonruang C, Thongchaeon P, Kunasol P. Community engagement; experience from the Thai Phase III Prime-Boost HIV vaccine trial, RV144 (Abstract). AIDS VACCINE 2010, Atlanta, USA, Sep 28-Oct 1, 2010 p.204 | |||
2009 |
Areechokchai D, Bowonwatanuwong C, Phonrat B, Pitisuttithum P, Maek-A-Nantawat W. Pregnancy Outcomes Among HIV-Infected Women Undergoing Antiretroviral Therapy. Open AIDS J. 2009 Mar 3; 3:8-13. | ||
| Kaewkungwal J, Pitisuttithum P, Nitayapan S, Khamboonruang C, Khamboonruang C, Thongchareon P, Kunasol P, Benenson M, Kim J. Assuring data quality of the phase III vaccine trial of ALVAC vaccine priming and AIDSVAX vaccine boosting in Thailand (Abstract). AIDS VACCINE 2009, Paris, France, October 19-22, 2009 p.182 | |||
| Kim JH, Kamasuta C, Trichavaroj R, Kaewkungwal J, Chantakulkij S, Ratto-Kim S, Eamsila C, Sukwit S, Nitayaphan S, Pitisuttihum P, Michael NL, Chiu J, Rerks-Ngarm S, de Souza MS. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial (Abstract). AIDS VACCINE 2009, Paris, France, October 19-22, 2009 p.54 | |||
| Maek-a-nantawat W, Phonrat B, Dhitavat J, Naksrisook S, Muanaum R, Ngamdee V, Pitisuttithum P. Safety and Efficacy of CKBM-A01, A Chinese Herbal Medicine, Among Asymptomatic HIV Patients. Southeast Asian J Trop Med Public Health 2009; 40(3):494-501. | |||
| Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373(9679):1949-57. | |||
| Nicholson O, DiCandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson MN, Mehrotra DV, Self S, Turner K, Sanchez J, Pitisuttithum P, Duerr A, Dubey S, Kierstead L, Casimiro D, Hammer SM. Safety and Immunogenicity of the MRKAd5 gag HIV-1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. In press. | |||
| Phonrat B, Ruengkris T, Naksrisook S, Intalapaporn K, Jirakorbchaipong P, Pitisuttithum P. Psychosocial Burden of Women with Abnormal Pap Smears. Southeast Asian J Trop Med Public Health 2009; 40(3):593-601. | |||
| Pitisuttithum P, Rerks-Ngarm S, Kaewkungwal J, Nitayaphan S, Khamboonruang C, Kunasol P, Suntharasamai P, Benenson MW, Kim JH. Recruitment, retention and participation impact events among women participating in phase III community trial in Thailand (Abstract). AIDS VACCINE 2009, Paris, France, October 19-22, 2009 p.170 | |||
| Rerks-Ngarm S, Pitisuttithum P, Kunasol P, Kim J. Phase III trial of HIV prime-boost vaccine combination in Thailand: result of final analysis (Abstract). AIDS VACCINE 2009, Paris, France, October 19-22, 2009 p.20 | |||
| Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361(23):2209-20. | |||
| Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee D, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Walker LM, Poignard P, Wrin T, Fast PE, Burton DR, Koff WC. Human Immunodeficiency Virus Type1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High Throughput Neuralization Assay together with an Analytical Selection Algorithum. J Virol 2009; 83(14):7337-48 | |||
| Songthap A, Pitisuttithum P, Kaewkungwal J, Fungladda W, Bussaratid V, Koonsaeng S. Knowledge, Attitude, and Acceptability of a Human Papillomavirus Vaccine among Healthcare Providers. Southeast Asian J Trop Med Public Health 2009; 40(5):1048-56. | |||
| Suntharasamai P, Martin M, Vanichseni S, Griensven FV, Mock PA, Pitisuttithum P, Tappero JW, Sangkum U, Kitayaporn D, Gurwith M, Choopanya. Factors associated with incarceration and incident human immunodeficiency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999-2003. Addiction 2009; 104, 235-242 | |||
| Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW; Protocol G Principal Investigators, Miiro G, Serwanga J, Pozniak A, McPhee D, Manigart O, Mwananyanda L, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Allen S, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target. Science. 2009;326:285-88. | |||
2008 |
Chamnachanan S, Tu A K, Tansuphasawadiku S, Phonrat B, Pitisuttithum P, Dhitavat J. Pulmonary tuberculosis treatment outcomes in HIV infected patients on antiretroviral therapy. International journal of infectious diseases, 2008 Jun 2; 12: s23-s23,52 suppl. | ||
| Excler JL, Pitisuttithum P, Rerks-Ngarm S, Shao Y, Zhang L, Tamashiro H, et al. Expanding Research Capacity and Accelerating AIDS Vaccine Development in Asia. Southeast Asian J Trop Med Public Health 2008; 39(4):766-784 | |||
| J. Kaewkungwal, P. Pitisuttithum, S. Nitayapan, C. Khamboonruang, P. Thongchareon, P. Kunasol, R. Paris, M. Benenson, J. Kim, S Rerks-Ngarm, MoPH TAVEG. Monitoring selection bias in phase III vaccine trail of ALVAC vaccine priming, AIDSVAX vaccine boosting in Thailand (Abstract). AIDS 2008, Mexico, August 3 - 8, 2008. Abstract Book vol. 2, p.118-119. | |||
| Kaewkungwal J, Pitisuttithum P, Nitayapan S, Khamboonruang C, Thongchareon P, Kunasol P, Paris R, Benenson M, Kim J, Rerks-Ngarm S, MoPH TAVEG. Monitoring selection bias in phase III vaccine trail of ALVAC vaccine priming, AIDSVAX vaccine boosting in Thailand (Abstract). AIDS 2008, Mexico, August 3 - 8, 2008. Abstract Book vol. 2, p.118-119 | |||
| Liangthorachon C, Khowsroy K, Boondao R, Lothong K, Sabmee Y, Rerks-Ngarm S, Kim JH, Pitisuttithum P. Knowledge and Expecatation of Participants in the Phase III HIV Vaccine Trial in Preparation for the Results of the Efficacy Interim Analysis (Abstract). AIDS VACCINE 2008, Cape Town, South Africa, October 13-16, 2008 p.174 | |||
| Maek-a-nantawat W, Phonrat B, Dhitavat J, Naksrisook S, Muanaum R, Ngamdee V, Pitisuttithum P. Safety and Efficacy of CKBM-A01, a Chinese Herbal Medicine, Among Asymptomatic HIV Patients. Southeast Asian J Trop Med Public Health 2008 (in press). | |||
| Naksrisook S, Phonrat B, Ruengkris T, Intalapaporn K, Pitisuttithum P, Jirakorbchaipong P. Psychosocial Burden of Abnormal Pap in Thailand (Poster Presentation). Pharmacoeconomics and Outcomes Research in Thailand: A Stepping Stone Toward National Drug Policy, Bangkok, Thailand, May 12-13, 2008 | |||
| Pitisuttithum P. AIDS Vaccine Research in Thailand (Abstract). 21st Joint Meeting of the AIDS Panels, Tokyo, Japan, September 10-12, 2008. | |||
| Pitisuttithum P. Clinical Trial and Principal of ICH GCP (Presentation). CU Cooperative Study Group, Maehongson, Thailand, January 11-13, 2008 | |||
| Pitisuttithum P. Herpes Zoster and post herpetic neuralgia-the Thailand perspective (Presentation). 13th International Congress on Infectious Diseases, Kuala Lumpur, Malaysia, June 19-22, 2008. | |||
| Pitisuttithum P. HIV vaccine research in Thailand: lessons learned. Expert Review of Vaccines. 2008 Apr; 7(3): 311-7 | |||
| Pitisuttithum P AIDS Vaccines Research Project. Medical Time 2008; 9(213): 50-52 | |||
| Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maekanantawat W, Pungpak S, Suntharasamai P, Vanijanonta S, Benenson MW, Kim JH. Retention Activities of Clinical Sites to Ensure Compliance among Participants in the Phase III Community Trial in Thailand (Abstract). AIDS VACCINE 2008, Cape Town, South Africa, October 13-16, 2008 p.173 | |||
| Pitisuttithum P, Rerks-Ngarm S, Kaewkungwal J, Nitayaphan S, Benenson M, Paris R, Michael N, Kim J, Khamboonruang C, Kunasol P. The Follow-up Phase of the Phase III Community Trial: Current Activities (Oral Presentation). AIDS VACCINE 2008, Cape Town, South Africa, October 13-16, 2008 p.64 | |||
| Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kim J, Kaewkungwal J, Gurunathan S, Gurwith M, Micahel N, Khamboonruang C, Thongcharoen P, Kunasol P. Phase III Trial of HIV Prime-Boost Vaccine Combination in Thailand: Follow up Phase (Abstract). AIDS VACCINE 2008, Cape Town, South Africa, October 13-16, 2008 p.176 | |||
2007 |
Ackland J, Allen S, Barth-Jones D, Birx D, Chomba E, Churchyard G, Duerr A, Jin S, Johnston M, Fast PE, Fix A, Foulkes M, Follmann D, Hutubessy R, Malone S, Gray R, Indrayan A, Levin J, Mathieson BJ, Mastro TD, McNeil J, Osmanov S, Pitisuttithum P, et al. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines'. AIDS 2007; 21(4):539-46. | ||
| Hammer S, Miller M, Pape J, Pitisuttithum P, Suriyanon V, Nitayaphan S, Sanchez J, Kallas E, Harro C, Gray G, Cadinali M, Turner K, Sun X, Mehrotra D, Quirk E. Safety and immunogenicity of the MRKAd5 gag HIV-1 vaccine in a worldwide phase I study of healthy adults (Merck V520-018/HVTN 050) (Abstract). AIDS VACCINE 2007, Seattle, USA, August 20-23, 2007 p.59 | |||
| Maek-A-Nantawat W, Tansuphaswadikul S, Aung S, Phonrat B, Kaewkungwal J, Pitisuttithum P. Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4 count. Allergy 2007; 62: 160. | |||
| Namwat C, Morgan P, Premsri N, Debyasuvarn T, Pitisuttithum P, Bussaratid V, Benenson M, Kim JH. Social Impact of participation in a phase III HIV vaccine trial in Thailand (Abstract). AIDS VACCINE 2007, Seattle, USA, August 20-23, 2007 p.105 | |||
| Osmanov S, Ackland J, Allen S, Barth-Jones D, Birx D, Chomba E, Churchyard G, Duerr A, Jin SG, Johnston M, Fast PE, Fix A, Foulkes M, Follmann D, Hutubessy R, Malone S, Gray R, Indrayan A, Levin J, Mathieson BJ, Mastro TD, McNeil J, Pitisuttithum P, et al. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York , USA . Aids2007; 21(4):539-46. | |||
| Paris RM, Bejrachandra S, Thongcharoen P, Nitayaphan S, Suriyanon V, Pitisuttithum P, Sambor A, Barnett S, Gurunathan S, Gurwith M, Kim S, MS de Souza, Polonis VR, Kim JH. HLA Class II alleles and neutralizing antibody responses to HIV-1 protein subunit boosting in a Thai population (Abstract). AIDS VACCINE 2007, Seattle, USA, August 20-23, 2007 p.135 | |||
| Pitisuttithum P, Choopanya K, Bussaratid V, Vanichseni S, Griensven FV, Phonrat B, Martin M, Vimutsunthorn E, Sangkum U, Kitayaporn D, Tappero JW, Heyward W, Francis D. Social Harms in Injecting Drug Users Participating in the First Phase III HIV Vaccine Trial in Thailand. J Med Assoc Thai 2007; 90 (11): 2441-2448 | |||
| Pitisuttithum P, Rerks-Ngarm S, Kaewkungwal J, Nitayaphan S, Khamboonruang C, Kunasol P, Benenson M, Kim J. Women participation in the phase III efficacy trial of ALVAC HIV-1 vaccine priming, AIDSVAX vaccine boosting in Thailand (Abstract). AIDS VACCINE 2007, Seattle, USA, August 20-23, 2007 p.92 | |||
| Pitisuttithum P. Thailand’s eExperiences in Conducting HPV Vaccine Trials and HPV Vaccine Update (Abstract). National Cancer Conference, Bangkok, Thailand, December 12-14, 2007 p.47 | |||
| Premsri N, Namwat C, Rerks-Ngarm S, Kunasol P, Khamboonreaung C, Chunsuttiwat S, Wattana S, Wiriyakijja W, Kim JH, Benenson MW, Pitisuttithum P, Nittayaphan S. Integration of community engagement activities support the prime-boost phase III HIV vaccine trial in Thailand (Abstract). AIDS VACCINE 2007, Seattle, USA, August 20-23, 2007 p.85 | |||
| Rerks-Ngarm S, Chunsuttiwat S, Pitisuttithum P, Nittayaphan S, Kaewkungwal J, Kim JH, Wattana S, Wiriyakijja W, Thongchareon P, Kunasol P, Khamboonreaung C. Thai Prime-boost HIV vaccine phase III trial: update 2007 (Abstract). AIDS VACCINE 2007, Seattle, USA, August 20-23, 2007 p.102 | |||
| Saito W, Pitisuttithum P, Tansuphasawadikul S, Dhitivat J, Phonrat B, Chamnachanan S, Kim J. Outcome of Tuberculosis in Advanced HIV-Infected Patients on Antiretroviral Therapy (Abstract). IAS 2007, Sydney, Australia, July 22-25, 2007. | |||
| Tansuphaswadikul S, Aung SE, Phonrat B, Kaewkungwal J, Pitisuttithum P, Maek-a-nantawat W. Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4 count. Asian Pac J Allergy Immunol. 2007 Jun-Sep;25(2-3):147-54. | |||
| Tansuphasawadikul S, Saito W, Kim J, Phonrat B, Dhitivat J, Chamnachanan S, Pitisuttithum P. Outcomes in HIV-Infected Patients on Antiretroviral Therapy with Tuberculosis. Southeast Asian J Trop Med Public Health 2007; 38(6):1053-1060 | |||
2006 |
Getahun A, Tansuphasawadikul S, Desakorn V, Dhitavat J, Pitisuttithum P. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection. J Med Assoc Thai. 2006 Sep;89(9):1472-8. | ||
| Gupta SB, Mast CT, Wolfe ND, Novitsky V, Dubey SA, Kallas EG, Schechter M, Mbewe B, Vardas E, Pitisuttithum P, Burke D, Freed D, Mogg R, Coplan PM Condra JH, Long RS, Anderson K, Casimiro DR, Shiver JW, Straus WL. Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon. J Acquir Immune Defic Syndr. 2006; 42(2):135-9 | |||
| Pitisuttithum P. Chapter 3 HIV Vaccine Research in Thailand National Perspective: Overview of HIV Vaccine Research in Thailand. In : Pitisuttithum P, Francis DP, Esparza J, Thongcharoen P, eds. HIV Vaccine Research and Development in Thailand. Bangkok:Amarin Printing and Publishing Public Company; 2006:83-92. | |||
| Pitisuttithum P, Francis DP, Esaparza J, Thongcharoen P. Chapter 8 Epilogue: Lessons Learnt. In : Pitisuttithum P, Francis DP, Esparza J, Thongcharoen P, eds. HIV Vaccine Research and Development in Thailand. Bangkok: Amarin Printing and Publishing Public Company; 2006:337-342. | |||
| Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K. Randomized, Double-Blind, Placebo-Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV-1 Vaccine among Injection Drug Users in Bangkok, Thailand. J Infect Dis. 2006 Dec 15; 194(12):1661-1671. | |||
| Pitisuttithum P, Migasena S, Singhasivanon P. Chapter 4 Phase I/II HIV Vaccine Trials in Thailand: The Vaccine Trial Center, Faculty of Tropical Medecine, Mahidol University. In : Pitisuttithum P, Francis DP, Esparza J, Thongcharoen P, eds. HIV Vaccine Research and Development in Thailand. Bangkok: Amarin Printing and Publishing Public Company; 2006: 131-150. | |||
| Pitisuttithum P, Vanichseni S, Kitayaporn D, Choopanya K. Chapter 7 Conducting Phase III Trials of Candidate HIV Vaccines:Phase III Efficacy Trial of Bivalent B/E rgp 120 HIV Vaccine (AIDSVAX® B/E) in Bangkok. In: Pitisutthithum P, Francis DP, Esparza J, Thongcaroen P, eds, HIV Vaccine Research and Development in Thailand. Bangkok: Amarin Printing and Publishing Public Company; 2006:275-290. | |||
| Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, Graham DR, Greenberg RN, Hadley S, Langston A, Negroni R, Perfect JR, Pitisuttithum P, Restrepo A, Schiller G, Pedicone L, Ullmann AJ. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006; 42(12):1726-34 | |||
| Rerks-Ngam S, Pitisuttithum P, Kitayaporn D, et al. Chapter 7 Conducting Phase III Trials of Candidate HIV Vaccines:The Rayong-Chonburi Community Phase III HIV Vaccine Trial. In : Pitisuttithum P, Francis DP, Esparza J, Thongcharoen P, eds. HIV Vaccine Research and Development in Thailand. Bangkok: Amarin Printing and Publishing Public Company; 2006:293-305. | |||
| Tansuphaswadikul S, Maek-a-nantawat W, Phonrat B, Boonpok L, Getahun A, Pitisuttithum P. Comparison of One Week with Two Week Regimens of Amphotericine B Both followed by Fluconazole in the Treatment of Cryptococcal Meningitis among AIDS Patients. J Med Assoc Thai 2006; 89(10):1677-1685 | |||
2005 |
Coplan PM, Gupta SB, Dubey SA, Pitisuttithum P, Nikas A, Mbewe B, Vardas E, Schechter M, Kallas EG, freed DC, fu TM, Mast CT, Puthavathana P, Kublin J, Brown Collins K, Chisi J, Pendame R, Thaler SJ, Gray G, McIntyre J, Straus WL, Condra JH, Mehrotra DV, Guess HA, Emini EA, Shiver JW. Cross-reactivity of anti-HIV-1 Tcell immune responses among the major HIV-1 Clades in HIV-1-Positive individuals from 4 continents. J Infect Dis 2005; 191:1427-34. | ||
| Desakorn V, Dondorp AM, Silamut K, Pongtavornpinyo W, Sahassananda D, Chotivanich K, Pitisuttithum P, Smithyman AM, Day NP, White NJ. Stage –dependent production and release of histidine-rich protein 2 by Plasmodium falciparum. Trans R Soc Trop Med Hyg 2005:99 (7):517-24 | |||
| Dondorp AM, Desakorn V, Pongtavornpinyo W, Sahassananda D, Silamut K, Chotivanich K, Newton PN, Pitisuttithum P, Smithyman AM, White NJ, Day NP. Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med 2005:2(8):e204 | |||
| Jenkins RA, Thapinta D, Morgan PA, Wongkamhaeng S, Sornsathapornkul P, Bussaratid V, Sontirat A, Pitisuttithum P, Thongchareoen P, Khamboonruang C, Suriyanon V, Nitayaphan S, Brown AE; Thai AIDS Vaccine Evaluation Group. Behavioral and social issues among volunteers in a preventive HIV vaccine trial in Thailand. J Acquir Immune Defic Syndr 2005:15:40(5):592-599 | |||
| Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Brown AE, Gurunathan S, Tartaglia J, Heyward WL, McNeil JG, Birx DL, de Souza MS; Thai AIDS Vaccine Evaluation Group, Thailand. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005;23:2522-9. | |||
| Knauer A, Das AK, Tansuphasawadikul S, Supanaranond W, Pitisuttithum P, Wernsdorfer WH. Clinical features, aetiology and short-term outcome of interstitial pneumonitis in HIV/AIDS patients at Bamrasnaradura Hospital, Nonthaburi, Thailand. Wien Klin Wochenschr 2005: 117 Supplement 4:49-55 | |||
| Pitisutithum P. HIV-1 prophylactic vaccine trials in Thailand. Curr HIV Res 2005;3:17-30. | |||
| Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S, Hare RS, Hardalo CJ. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005:56:745-755 | |||
| Tansuphasawadikul S, Pitisuttithum P, Knauer AD, Supanaranond W, Kaewkungwal J, Karmacharya BM, Chovavanich A. Clinical features, etiology and short term outcomes of interstitial pneumonitis in HIV/AIDS patients. Southeast Asian J Trop Med Public Health 2005 :36(6):1469-1478 | |||
| Tin EE, Bowonwatanuwong C, Desakorn V, Wilairatana P, Krudsood S, Pitisuttithum P. The efficacy and adverse effects of GPO-VIR (Stavudine+lamivudine+nevirapine) in treatment naïve adult HIV patients. Southeast Asian J Trop Med Public Health 2005:36 (2):362-369 | |||
| Van Griensven F, Pitisuttithum P, Vanichseni S, Wichienkuer P, Tappero JW, Sangkum U, Kitayaporn D, Phasithiphol B, Orelind K, Choopanya K. Trends in the injection of midazolam and other drug and needle sharing among injection drug users enrolled in the AIDSVAX B/E HIV-1 vaccine trial in Bangkok, Thailand. International Journal of Drug Policy 16(2005)171-175. | |||
2004 |
Nitayaphan S, Pitisuttithum P, Karnasuta C, Eamsila C, de Souza M, Morgan P, Polonis V, Benenson M, VanCott T, Ratto-Kim S, Kim J, Thapinta D, Garnern R, Bussaratid V, Singharaj P, el-Habib R, Gurunathan S, Heyward W, Birx D, McNeil J, Brown AE; Thai AIDS Vaccine Evaluation Group. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 2004; 190:702-6. | ||
| Paris R, Bejrachandra S, Karnasuta C, Chandanayingyong D, Kunachiwa W, Leetrakool N, Prakalapakorn S, Thongcharoen P, Nittayaphan S, Pitisuttithum P, Suriyanon V, Guruthan S, McNeil JG. Brown AE, Birx DL, de Souza M. HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp 120 or oligomeric gp 160 protein boosting. Tissue Antigens 2004;64:251-6. | |||
| Pitisuttithum P, Berman PW, Phonrat B, Suntharasamai P, Raktham S, Srisuwanvilai LO,Hirunras K, Kitayaporn D, Kaewkangwal J, Migasena S, Sheppard HW, Li E, Chernow M, Peterson ML, Shibata R, Heyward WL, Francis DP. Phase I/II Study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr 2004;37:1160-5. | |||
| Van Griensven F, KeawKungwal J, Tappero JW, Sangkum U, Pitisuttithum P, Vanichseni S, Suntharasamai P, Orelind K, Gee C, Choopanya K for the Bangkok Vaccine Evaluation Group. Lack of increased HIV risk behavior among infection drug users participating in the AIDSVAX B/E HIV vaccine trial, Bangkok, Thailand. AIDS 2004; 18:295-301 | |||
| Vanichseni S, Tappero JW, Pitisuttithum P, Kitayaporn D, Mastro TD, Vimutisunthorn E, Van Griensven F, Heyward WL, Francis DP, Choopanya K, for the Bangkok Vaccine Evaluation Group. Recruitment, screening and characteristics of infection drug users participating in the AIDSVAX B/E HIV vaccine trial, Bangkok, Thailand. AIDS 2004; 18:311-316. | |||
2003 |
Kim JH, Pitisuttithum P, Kamboonruang C, Chuenchitra T, Mascola J, Frankel SS, DeSouza MS, Polonis V, McLinden R, Sambor A, Brown AE, Phonrat B, Rungruengthanakit K, Duliege AM, Robb ML, Mcneil J, Birx DL; Thai AIDS Vaccine Evaluation Group. Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1.AIDS Res Hum Retroviruses.2003 Sep; 19(9): 807-16 | ||
| Maek-A-Nantawat W, Pitisuttithum P, Bussaratid V, Chamnachanan S, Naksrisook S, Peonim W, Thantamnu N, Muanaum R, Ngamdee S. 6-month evaluation of JinHuang “Chinese Herbal Medicine” study in asymptomatic HIV infected Thais. Southeast Asian J Trop Med Public Health. 2003; 34:379-84. | |||
| Maek-A-Nantawat W, Pitisuttithum P, Phonrat B, Bussaratid V, Naksrisook S, Peonim W, Thantamnu N, Muanaum R. Evaluation of attitude, risk behavior and expectations among Thai participants in Phase I/II HIV/AIDS Vaccine Trials. J Med Assoc Thai.2003; 86:299-307. | |||
| Pitisuttithum P, Nitayaphan S, Thongcharoen P, Khamboonruang C, Kim J, De Souza M, Chuenchitra T, Garner R.P, Thapinta D, Polonis V, Ratto- Kim S, Chanbancherd P, Chiu J, Birx L.D, Duliege A.M, McNeil J.G, Brown A.E, Safety and Immunogenicity of Combinations of Recombinant Subtype E and B HIV-1 Envelop gp120 Vaccines in Healthy Thai Adults. J Infect Dis 2003; 188(2): 219-27 | |||
| Punnee Pitisuttithum. Chapter 44: Incidence of Foodborne Illness in Southeast Asia. In: Miliotis MD, Bier JW, eds. International Handbook of Foodborne Pathogens. New York: Marcel Dekker, Inc.; 2003: 711-732. | |||
2002
|
Almond N, Anzala O, Bektimirov T, Berman P, Birx D, Carvalheiro J, Chongprasert S, Cichutek K, Darbyshire J, Duarte C, Ensoli B, Fenyo EM, Girard M, Goldenthal K, Golding H, Holmes H, Johnston M, Mallet L, Mawle A, Mugerwa R, Pitisuttithum P, Rees H, Robertson J, Rowland-Jones S, Sang G, Schild G, Shao Y, Sheets R, Takemori, T, Tramont E, Vandepapeliere P, Van der Groen G, Weiner D, Widdus R, Esparza J, Griffiths E, Knezevic I, Milstien J, Osmanov S, Susuki Y, Wood D. Scientific considerations for the regulation and clinical evaluation of HIV/AIDS preventive vaccines: Report* from a WHO-UNAIDS consultation 13-15 March 2001, Geneva, Switzerland. AIDS 2002; 16(10), W15-W25. | ||
| Bussaratid V, Tansupasawaskul S, Simpson A, Pitisuttithum P, Phonrat B, Howe P, White NJ. Clinical and mycological responses to fluconazole and fluconazole MIC in oropharyngeal candidiasis in HIV-infected patients.J Med Assoc Thai 2002; 85:757-64. | |||
| Desakorn V, Simpson AJ, Wuthiekanun V, Sahassananda D, Rajanuwong A, Pitisuttithum P, Howe PA, Smith MD, White NJ. Development and evaluation of rapid urinary antigen detection tests for diagnosis of penicillosis marneffei. J Clin Microbiol 2002; 40:3179-83. | |||
| Newton PN, Thai le H, Tip NQ, Short JM, Chierakul W, Rajanuwong A, Pitisuttithum P, Chasombat S , Phonrat B, Maek-A-Nantawat W,Teaunadi R, Lalloo DG, White NJ. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis 2002; 35:769-72. | |||
| Pitisuttithum P, Cohen MB, Phonrat B, Suthisarnsunton U, Bussaratid V, Desakorn V, Phumratanaprapin W, Singhasivanon P, Looareesuwan S, Schiff GM, Ivanoff B, Lang D. A human volunteers challenge model using frozen bacteria of the new epidemic serotype, V.cholerae O139 in Thai volunteers. Vaccine 2002; 20:920-5. | |||
| Pitisuttithum P, Nitayaphan S, M de Souza, Kim J, Polonis V, Ratoo-Kim S, Heyward W, Gurunathan S, Brown A and Thai AIDS Vaccine Evaluation Group. Live Recombinant ALVAC-HIV (vCP1521) Priming with AIDSVAX B/E Boosting in Thailand: Safety & Immunogenicity (Abstract). XIV International AIDS Conference. Barcelona July 7-12 2002. | |||
| Pitisuttithum P, Suntharasamai P, Van Griensven S, Vanichsen I, Sangkum U, Hirunras K, Migasena S and Choopanya K. Incarceration among injecting drug users (IDUs) participating in the AIDSVAX B/E vaccine efficacy trial in Bangkok Thailand (Abstract). XIV International AIDS Conference. Barcelona 2002. | |||
| Pukrittayakamee S, Pitisuttithum P, Zhang H, Jantra A, Wanwimolruk S, White NJ. Effects of cigarette smoking on quinine pharmacokinetics in malaria. Eur J Clin Pharmacol 2002; 58:315-9. | |||
| Putong NM, Pitisuttithum P, Supanaranond W, Phonrat B, Tansuphasawadikul S, Silachamroon U, Yuda HC, Bussaratid V, Aswapokee N. Mycobacterium tuberculosis infection among HIV/AIDS patients in Thailand: clinical manifestations and outcomes. Southeast Asian J Trop Med Public Health 2002; 33:346-51 | |||
| Thapinta D, Jenkins RA, morgan PA, Chiu J, Boenim W, Bussaratid V,Chaddic C, Naksrisook S, Phonrat B, Sirijongdee N, Sornsathapornkul P, Sontirat A, Srisaengchai P, Suwanarach C, Wongkamhaeng S, Brown AE, Khamboonruang C, Nitayaphan S, Pitisuttithum P, Thongchareon P. Recruiting volunteers for a multisite phase I/II HIV preventive vaccine trial in Thailand. J Acquir Immune Defic Syndr 2002; 30:503-13. | |||
2001 |
Meak-A-Nantawat W, Pitisuttithum P, Phonrat B, Budsaratid V, Naksrisook S, Peonim W, Thantamnu N and Muanom R, Knowledge behavioral risk and psychological assessment of Thai volunteers participating in phase I/II HIV/AIDS vaccine trials. 6th International Congress on AIDS in Asia and the Pacific Melbourne, Australia, October 5 – 10, 2001 | ||
| Pitisuttithum P, Choopanya K, Phonrat B, Vanichseni S, Sangkum U, Heyward W, Gee C. for the Bangkok Vaccine Evaluation Group. The Conduct of Good Clinical Practices (GCP) in the First HIV-1 Vaccine Efficacy Trial in a Developing Country – Bangkok, Thailand (Abstract). 6th International Congress on AIDS in Asia and the Pacific, Melbourne, Australia, Oct. 5-10, 2001 | |||
| Pitisuttithum P, Cohen M.B., Phonrat B., Suthisarnsuntorn U., Bussaratid V., Desakorn V., Phumratanaprapin W, et al. A human volunteer challenge model using frozen bacteria of the new epidemic serotype, V. cholerae O139 in Thai volunteers. Vaccine 2001; 20 (5-6): 920-925. | |||
| Pitisuttithum P, Nitayaphan S, Phonrat B, Heyward W, Gurunathan S, Kim J, Brown A and the Thai AIDS Vaccine Evaluation Group. Safety of Live Recombinant ALVAC – HIV (vCP1521) Priming with AIDSVAXTM B/E Boosting in Thai HIV – 1 negative Participants: Preliminary Results (Abstract). 6th International Congress on AIDS in Asia and the Pacific, Melbourne, Australia , October 5 – 10 , 2001 | |||
| Pitisuttithum P, Tansuphasawadikul S, Simpson AJ, Howe PA, White NJ. A prospective study of AIDS-associated cryptococcal meningitis in Thailand: Treated with high-dose amphotericin B. J Infect 2001; 43:226-33. | |||
| Pitisuttithum P, The Bangkok Vaccine Evaluation Group. Thailand‘s Success in Moving to the First Phase III HIV Vaccine Efficacy Trial in a Developing Country (Abstract). AIDS VACCINE 2001, Philadelphia, USA, September 5 – 8, 2001p.144 | |||
2000 |
Migasena S, Suntharasamai P, Pitisuttithum P, Kitayaporn D, Wasi C, Huang W, Vanichseni S, Koompong C, Kaewkungwal J, Raktham S, ppolito T, Hanson C, Gregory T, Heyward WL, Berman P, Francis D. AIDSVAXÒ (MN) in Bangkok injecting drug user: A report on safety and immunogenicity including mocrophage tropic virus neutralizing. AIDS Res Hum Retroviruses 2000; 16:655-63. | ||
| Pitisuttithum P, and Thai AIDS Vaccine Evaluation Group. Phase II Trial of HIV-1 Subtype E and B gp120 Vaccines in Seronegative Thai Adults. (Abstract). XII International AIDS Conference Durban, South Africa, 9-14 July 2000 | |||
| Pitisuttithum P, Bangkok Vaccine Evaluation Group. Social harm monitoring among injecting drug users (IDUs) in a phase III HIV vaccine trial in Bangkok, Thailand-preliminary results.(Abstract). XII International AIDS Conference Durban, South Africa, 9-14 July 2000 p.443 | |||
| Pitisuttithum P, Phonrat B, Suntharasamai P, Raktham S, Srisuwanvilai L, Hiranrus K, Kitayaporn D., et al. Initial Report of a Phase I/II Safety and Immunogenicity Trial AIDSVSXTM B/E rgp120 HIV Vaccine – Bangkok, Thailand. (Abstract). XII International AIDS Conference Durban,South Africa, 9-14 July 2000 | |||
| Pitisuttithum P, Phonrat B, Suntharasamai P, Raktham S, Srisuwanvilai L, Kitayaporn D, Kaewkangwal J, Migasean S, Hiranrus K, Berman P, Chernow M and Francis D. Phase I/II Safety and Immunogenicity Trial of Bivalent rgp120 HIV Vaccine (AIDSVAXTM B/E) in Bangkok, Thailand-Initial Report (Abstract). The Third Annual Conference on Vaccine Research, Washington DC. April 30-May 2, 2000 p.48 | |||
1999 |
Pitisuttithum P, Cohen MB, Phonrat B, Suthisarnsuntorn U, Bussaratid V, Phumratanaprapin W, Singhasivanon P, Looareesuwan S, Giannella RA, Schiff GM, Ivanoff B and Lang D. Validation of a human volunteer challenge model using frozen bacteria of the new epidemic serotype V.cholerae O139. Comparison of the inoculum dose response between North American and thai volunteers (Abstract). The 35th US-Japan Cholera and other Bacterial Enteric Infectious Baltimore, MD. December 3-5 1999; p.37 | ||
| Pitisuttithum P, Phonrat B, Suntharasamai P, Migasena S, Bussaratid V, Francis DP, McNeil J, Brown A, Duliege AM. HIV-1 Vaccine trial at the Vaccine Trial Centre (VTC), Bangkok. (Abstract). The second annual conference on Vaccine research Bethesda, 28-30 March 1999 | |||
| Pitisuttithum P, Phonrat B, Suntharasamai P, Raktham S, Srisuwanvilai L, Ktitayaporn D, Kaewkangwal J, Migasena S, Hiranrus K, Berman P and Francis D. A Phase I/II Trial to Evaluate the Safety and Immunogenicity of AIDSVAXTM B/E Vaccine Bangkok, Thailand-Priliminary Results. Kuala Lumpur, 23-27 October 1999 | |||
| Pitisuttithum P, Tongcharoen P, Khamboonruang C, Nitayaphan S, Chiu J, Brown A. and McNeil J. HIV Subtype E gp 120 Vaccine Trial (Phase II) in Seronegative Thai Adults. Kuala Lumpur, 23-27 October 1999 | |||
1998 |
Francis D, Gregory T, McElrath J, Belshe R, Gorse G, Migasena S, Kitayaporn D, Pitisuttithum P, et al Advancing AIDSVAXTM to Phase III Safety, Immunogenicity and Plans for Phase III . AIDS Res Human Retroviruses 1998; 14 : S 325-31 | ||
| Migasina S, Simasathien S, Samakoses R, Pitisuttithum P, Heath J, Bellini W and Bennett J. Adverse impact of infections on antibody responses to measles vaccination Vaccine.1998;16(6):647-52 | |||
| Pitisuttithum P, Kambooruang C, Suntharasamai P, et al. Clinical response to HIV Thai E /MF59 vaccine administer of alone or combined with SF2 gp120 antigen in healthy volunteers (Abstract) 12th World AIDS Conference Geneva. June 28-July 3, 1998 page 636 | |||
| Tansuphasawadikul S, Poprawski DM, Pitisuttithum P and Phonrat B. Non adherence in tuberculosis treatment among HIV patients attending Bamrasnaradura Hospital Nonthaburi. J Med assoc thai 1998; 81:964-9 | |||
1997 |
Migasena S, Heppner DG, Kyle DE, Chongsuphajaisiddhi T, Gordon DM, Suntharasamai P, Permpanich B, Brockman A, Pitisuttithum P, et al. SPf66 malaria vaccine is safe and immunogenic in malaria native adults in Thailand. Acta Tropica 1997; 67:215-27 | ||
| Migasena S, Simasathien S, Desakorn V, Phonrat B, Suntharasamai P Pitisuttithum P, Aree C, Naksrisook S, Supeeranun L, Samakoses R, Meurice F. Seroprevalence of varicella-zoster Virus Antibody in Thailand. Int J Infect Dis 1997; 2:26-30. | |||
| Looareesuwan S, Wilairatana P, Vanijianonta S, Pitisuttithum P, Ratanapong Y and Andrial M. Monotherapy with sodium artesunate for uncomplicated falciparum malaria in Thailand: a comparison of 5-and 7- day regimens Acta Trop 1997;30;67(3):197-205 | |||
| Looareesuwan S, Wilairatana P, Viravan C, Vanijanonta S, Pitisuttithum P and Kyle DE. Open randomized trial of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated falciparum malaria. Am J Trop Med Hyg 1997; 56(6):613-7 | |||
| Pitisuttithum P, Migasena S, Laothai A, Suntharasamai P, et al. Risk behaviour and comprehension among intravenous drug users volunteered for HIV vaccine trial. J Med Assoc Thai 1997; 80(1):47-50 | |||
| Pitisuttithum P, Migasena S, Suntharasamai P and Raktham S. Experience to date with vaccine trial in recovering intravenous drug users: Lesson for the future. (Abstract). 4th International Congress on AIDS in Asia and the Pacific October 25-29,1997 p.360 | |||
| Simasathien S, Migasena S, Bellini W, Samakoses R, Pitisuttithum P, Bupodom W, Heath J, Anderson L and Bennett J. Measles vaccination of Thai infants by intranasal and subcutaneous routes: possible interference from respiratory infections. Vaccine 1997; 15(3): 329-34 | |||
| Suntharasamai P, Migasena S, Pitisuttithum P., et al. Recruiting recovering intravenous drug users for a HIV protective vaccine trial (Abstract). 4th international Congress on AIDS in Asia and the Pacific October 25-29, 1997 p.377 | |||
1996 |
Looareesuwan S, Viravan C, Vanijanonta S, Wilairatana P, Pitisuttithum P and Andrial M. Comparative Clinical Trial of Artesunate followed by Mefloquine in the treatment of acute uncomplicated falciparum malaria: two-and three day regimens. Ann J Trop Med Hyg 1996; 54(2):210-3 | ||
| Looareesuwan S, Wilairatana P, Vanijanonta S, Pitisuttithum P and Viravan C. Treatment of acute,uncomplicated falciparum malaria with oral dihydroartemisinin. Ann Trop Med Parasit 1996; 90(1):21-8 | |||
| Migasena S, Pitisuttithum P, Phonrat B. Combined Immunization of infants with oral and inactivated poliovirus vaccines:results of a randomized trial in the Gambia, Oman and Thailand. Bulletin of World Health Organization. 1996;74(3):253-68. | |||
| Migasena S, Sutharasamai P, Pitisuttithum P, Kitayaporn D, Wasi C,Vanichseni S, Koompong C, Kaewkungwal J, Raktham S, Ippolito T, Gregory T, Heyward WL and Francis DP. A phase I/II Trial of MN RGP 120 HIV-1 vaccine among injecting drug users Bangkok, Thailand Safety and Immunogenicity. (Abstract) XI Internation Conference on AIDS, Vancouver, July 7-12,1996p.41 | |||
| Pittisuttithum P, Migasena S, Suntharasamai P, Sutthan R, Perathamanond P, Wasi C,Schikan U, Peeters P and Tobia A. Hypericin: Safety and Antiretroviral activity in Thai HIV positive volunteers (Abstract). XI Interantion Conference on AIDS, Vancouver, July 7-12,1996 p.285 | |||
1995 |
Migasena S, Simasathien S, Samakoses R, Pitisuttithum P, Sangaroon P, Steenis GV, Beuvery C, Bugg H, Bishop R, Davidson B and Vesikari T. Simultaneous administration of oral rhesus-human reassortant tetravalent (RRV-TV) rotavirus vaccine and oral poliovirus vaccine (OPV) in Thai infants. Vaccine 1995; 13(2):168 | ||
| Pitisuttithum P, Phiboonnakit D, Chindanond D, Punpoonwong B, Leelasuphasri S and Vanijanond S. Intestinal Microsporidiosis: First reported case in Thailand. Southeast Asian J Trop Med Pub Hlth 1995; 26(2):378-80 | |||
| Pitisuttithum P, Supanaranond W and Chindanond D. A randomized comparative study of albendazole and thiabendazole in chronic strongyloidasis. Southeast Asian J Trop Med Pub Health 1995; 26(4):735-8 | |||
| Punpoowong B, Pitisuttithum P, Chindanon D, Phiboonnakit, D and Leelasuphasri S. Microsporidium: Modified technique for ligh microscopic diagnosis. J Med Assoc Thai 1995; 78(5):252-4 | |||
1994 |
Simasathien S, Migasena S, Samakoses R, Pitisuttithum P, Sangaroon P, Aree C, Bishop R, Bugg H, Davidson B and Vesikari T. Vaccination of Thai infants with rhesus-human reassortant tetravalent (PRV-TV) rotavirus vaccine Pediatr. Infect Dis J 1994;13(7):590 | ||
| Simasathien S, Migasena S, Beuvery C, Steenis G, Samakoses R, Pitisuttithum P and Vesikari T. Comparison of enhanced potency inactiated poliovirus vaccine (eIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants. Scan J Infect Dis1994; 26:731-8 | |||
1993 |
Pitisuttithum P, Migasena S, Prayurahong B, Supanaranond W, Suntharasamai P, Supeeranan L, Chantra A and Naksrisook S. Pasteur oral cholera vaccine studies of reactogenicity, clinical acceptability and immunogenicity in human volunteers. Southeast Asian J Trop Med Pub Hlth 1993; 24(1):126 | ||
1992 |
Su-arehawaratana P, Singharaj P, Taylor D N, Hoge C, Trofa A, Kuvanont K, Migasena S, Pitisuttithum P, Lim Y L, Losonsky G, Kaper JB, Wesserman SS, Cryz S, Echeverria P. and Levine MM. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis 1992;165(6):1042 | ||
| Suntharasamai P, Migasena S, Vongsthongsri U, Supanaranond W, Pitisuttithum P, Supeeranan L, Chantra A and Naksrisook S. Clinical and bacteriological studies of El Tor cholera after ingestion of known inocula in Thai volunteers. Vaccine 1992; 10(8):502 | |||
1991 |
Migasena S, Pitisuttithum P and Desakorn V. Gnathostoma larva migrans among guests of a New Year party. Southeast Asian J Trop Med Public Health. 1991 Dec;22 suppl:225-7 | ||
1990 |
Migasena S, Pitisuttithum P, Prayurahong B, Supanaranond W, Desakorn V, Suntharasamai P, Vongthongsri U and Levine MM. Clinical acceptability immunogenicity colonizing potential and transmissibility of0 attenuated (A-B+) Vibrio cholerae classical Inaba live oral vaccine strain CVD 103-HgR in healthy young Thai adults. Infect Immun 1989; 57:3261 | ||
| Pitisuttithum P, Migasena S, Juntra A, Supeeranun L and Naksrisuk S. Socioeconomic status and prevalence of interstial parasitic infection in Thai adults resideing in and around Bangkok metropolis. J Med Assoc Thai 1990; 73:522-3 | |||
| Pitisuttithum P, Migasena S, Suntharasamai P, Supanaranond W, Desakorn V and Prayurahong B. Immune responses following killed whole vibrio-B subunit oral cholera vaccine in human volunteers. Southeast Asian J Trop Med Pub Hlth 1990; 20:201-5 | |||
| Pitisuttithum P, Prayurahong B, Migasena S and Sunthrasamai P. Relationship of vibiocidal antibodies to history of cholera vaccination in Thai adult volunteers. Southeast Asian J Trop Med Pub Hlth 1990; 21:219-24 | |||
| Supanaranond W, Migasena S, Pitisuttithum P and Suntharasamai P. Health status of Thai volunteer in a cholera vaccine trial. J Med Assoc Thai 1990; 73(10): 548-51 | |||
1989 |
Migasena S, Desakorn V, Suntharasamai P, Pitisuttithum P, Prayurahong B, Supanaranond W and Black RE. Immunogenicity of two formulations of oral cholera vaccine comprised of killed whole vibrios and the B subunit of cholera toxin. Infect Immun 1989; 57(1): 117-20 | ||
| Migasena S, Pitisuttithum P, Prayurahong B, Suntharasamai P, Supanaranond W, Desakorn V, Vongthongsri U, Tall B, Ketley J, Losonsky G, et al. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. Infect Immun 1989; 57(11);3261-4 | |||
| Migasena S, Pitisuttithum P, Supanaranond W, Desakorn V, Prayurahong B and untharasamai P. Reactogenicity and immunogenicity of oral cholera vaccine in Thai volunteers. Southeast Asian J Trop Med Pub Hlth 1989; 19:423-8 | |||
| Migasena S, Pitisuttithum P, Suntharasamai P, Prayurahong B, Supanaranond W, Desakorn V and Black RE. Comparison of the reactivities and of immunogenicities of Procholeragenoid and the B-subunit of cholera toxin in Thai Volunteers. Infect Immun 1989; 57:1942-5 | |||
| Migasena S, Supanaranond W, Pitisuttithum P, Suntharasamai P and Supeeranun L. Dose finding studies of Procholeragenoid in Thai volunteers. Southeast Asian J Trop Med Pub Hlth 1989; 20:27-30 | |||
| Pitisuttithum P, Migasena S, Suntharasamai P, Supanaranond W, Desakorn V and Prayurahong B. Immune responses following killed whole vibrio-B subunit oral cholera vaccine in human volunteers. Southeast Asian J Trop Med Public Health 1989; 20(2):201-5 | |||
1988 |
Migasena S, Desakorn V, Suntharasamai P, Pitisuttithum P, Prayurahong B and Suntharasamai P. Reactogenicity and immunogenicity of oral cholera vaccine in Thai Volunteers. Southeast Asian J Trop Med Pub Hlth 1988; 19:423-8 | ||
| Pitisuttithum P, Migagena S, Suntharasama P and Supanaranond W. Factors influenzing the intestinal intubation in Thai adult volunteers. J Med Assoc Thai 1988; 71:351-4 |
Last updated:May 30, 2019
Copyright © 2008 Faculty of Tropical Medicine, Mahidol University. All rights reserved. Webmaster : tmwww@mahidol.ac.th |
||